TTOO vs. PAVM, MHUA, SSKN, GCTK, PYPD, PETV, MBOT, IINN, NXGL, and NEPH
Should you be buying T2 Biosystems stock or one of its competitors? The main competitors of T2 Biosystems include PAVmed (PAVM), Meihua International Medical Technologies (MHUA), STRATA Skin Sciences (SSKN), GlucoTrack (GCTK), PolyPid (PYPD), PetVivo (PETV), Microbot Medical (MBOT), Inspira Technologies Oxy B.H.N. (IINN), NEXGEL (NXGL), and Nephros (NEPH). These companies are all part of the "surgical & medical instruments" industry.
PAVmed (NASDAQ:PAVM) and T2 Biosystems (NASDAQ:TTOO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership, profitability and earnings.
In the previous week, PAVmed had 3 more articles in the media than T2 Biosystems. MarketBeat recorded 7 mentions for PAVmed and 4 mentions for T2 Biosystems. T2 Biosystems' average media sentiment score of -0.24 beat PAVmed's score of -0.81 indicating that PAVmed is being referred to more favorably in the media.
PAVmed has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, T2 Biosystems has a beta of 0.05, indicating that its stock price is 95% less volatile than the S&P 500.
T2 Biosystems has higher revenue and earnings than PAVmed.
T2 Biosystems has a net margin of -696.19% compared to T2 Biosystems' net margin of -2,617.25%.
PAVmed currently has a consensus target price of $21.00, suggesting a potential upside of 914.49%. T2 Biosystems has a consensus target price of $3.00, suggesting a potential downside of 19.35%. Given T2 Biosystems' higher possible upside, research analysts plainly believe PAVmed is more favorable than T2 Biosystems.
T2 Biosystems received 206 more outperform votes than PAVmed when rated by MarketBeat users. However, 65.79% of users gave PAVmed an outperform vote while only 64.65% of users gave T2 Biosystems an outperform vote.
19.9% of PAVmed shares are held by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are held by institutional investors. 12.6% of PAVmed shares are held by insiders. Comparatively, 0.1% of T2 Biosystems shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
PAVmed beats T2 Biosystems on 8 of the 13 factors compared between the two stocks.
Get T2 Biosystems News Delivered to You Automatically
Sign up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TTOO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
T2 Biosystems Competitors List
Related Companies and Tools
